期刊文献+

抗癫癎药物所致严重皮肤不良反应基因学研究进展 被引量:3

原文传递
导出
摘要 药物不良反应是指临床按正常用法、用量使用药物过程中发生的与治疗无关的不利或有害的反应,可见于10%~15%的住院患者。皮肤药物不良反应(cutaneous adverse drug reactions,CADR)是常见的药物不良反应,主要包括药疹、药物超敏反应综合征(drug hypersensitivity syndrome,DHS/HSS)、Stevens-Johnson综合征(Stevens-Johnson syndrome,SJS)及中毒性表皮坏死松解症(toxic epidermal necrolysis,TEN),
出处 《中华儿科杂志》 CAS CSCD 北大核心 2012年第12期906-908,共3页 Chinese Journal of Pediatrics
基金 湖北省自然科学基金(2009CDB099)
  • 相关文献

参考文献31

  • 1Roujeau JC. The spectrum of Steven-Johnson syndrome and toxic epidermal necrolysis: a clinic classification. J Invest Dermato, 1994, 102:28S-30S.
  • 2Yang CW, Hung SI, Juo CG, et al. HLA-B * 1502-bound peptides: implications for the pathogenesis of carbamazepine- induced Stevens-Johnson syndrome. J Allergy Clin Immunol, 2007, 120:870-877.
  • 3Mockenhaupt M. The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis. Expert Rev Clin Immunol, 2011, 7:803-813.
  • 4Wei CY, Ko TM, Shen CY, et al. A recent update of pharmacogenomics in drug-induced severe skin reactions. Drug Metab Pharmacokinet, 2012, 27 : 132-141.
  • 5Chung WH, Hung SI, Yang JY, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med, 2008, 14: 1343-1350.
  • 6Chung WH, Hung SI, Hong I-IS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature, 2004, 428 : 486.
  • 7Man CB, Kwan P, Baum L, et al. Association between HLA-B * 1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia, 2007, 48 : 1015-1018.
  • 8Lonjou C, Thomas L, Borot N, et al. A marker for Stevens- Johnson syndrome : ethnicity matters. Pharmacogenomics J, 2006, 6 : 265-268.
  • 9Alfirevic A, Jorgensen AL, Williamson PR, et al. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics, 2006, 7:813-818.
  • 10Locharemkul C, Loplumlert J, Limotai C, et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B * 1502 allele in Thai population. Epilepsia, 2008, 49 : 2087-2091.

二级参考文献23

  • 1Handoko KB, Pui J, Eugene P, et al. Influence of chemical structure on hypersensitivity reactions induced by antiepileptic drugs: the role of the aromatic ring[J]. Drug Safety, 2008, 31 (8): 695-702.
  • 2Chung WH, Huang SI, Hong US, et al. Medical genetics: a marker for Stevens-Johnson syndrome[J]. Nature, 2004, 428(4): 486.
  • 3Celeste M, Patrick K, Larry B, et al. Association between HLA-B^*1502 allele and antiepileptic drug-induced cutaneous reactions in ban Chinese[J]. Epilepsia, 2007, 48(5): 1015-1018.
  • 4Bunce M, O'Neill CM, Bamardo MC, et al. Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP)[J]. Tissue Antigens, 1995, 46 (5): 355-367.
  • 5Nassif A, Bensussan A, Dorothee G, et al. Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis[J]. J Invest Dermato, 2002, 118(4): 728-733.
  • 6Nasisbitt D J, Britschgi M, Wong G, et al. Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenolype and cytokine profile of drug-specific T cell clones [J]. Mol Pharmacol, 2003, 63(3): 732-741.
  • 7Nassif A, Bensussan A, Boumsell L, et al. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells [J]. J Allergy Clin Immunol, 2004, 114(5): 1209-1215.
  • 8Hung SI, Chung WH, Jee SH, et al. Gentic susceptibility to carbamazepine-induced cutaneous adverse drug reactions [J]. Pharmacogenet Genomics, 2006, 16(4): 297-306.
  • 9Lonjou C, Thomas L, Borot N, et al. A marker for Stevens-Johnson syndrome: ethnicity matters[J]. Pharmacogenomics J, 2006, 6(4): 265-268.
  • 10Griffin JW,Li CY,Ho n Ⅳ,et al,Guillain-Barre' syndrome innorthern China:the spectrum of neuropathological changes inclinically defined cases.Brain,1995,118:577-595.

共引文献27

同被引文献31

  • 1Tolaymat A, Nayak A, Geyer JD, et al. Diagnosis and management of childhood epilepsy[ J]. Curt Probl Pediatr Adolesc Health Care, 2015, 45 ( 1 ) :3-17.
  • 2Glauser TA, Loddenkemper T. Management of childhood epilepsy [J]. Continuum ( Minneap Minn), 2013, 19 (3 Epilepsy) : 656-681.
  • 3Berg AT, Berkovic SF, Brodie M J, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE commission on classification and terminology, 2005- 2009 [ J]. Epilepsia, 2010, 51 (4) :636-685.
  • 4Glauser TA, Cnaan A, Shinnar S, et al. Ethosuximide, valproie acid and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months [ J]. Epilepsia, 2013, 54 (1) :141-155.
  • 5Tangamomsuksan W, Chaiyakunapruk N, Somkrua R, et al. Relationship between the HLA-B * 1502 allele and earbamazepine-indueed Stevens-Johnson syndrome and toxic epidermal neerolysis : a systematic review and meta-analysis [ J ]. JAMA Dermatol, 2013, 149(9) :1025-1032.
  • 6Vajda FJ. Effect of anti-epileptic drug therapy on the unborn child [J].J Clin Neurosei, 2014, 21(5) :716-721.
  • 7Privitera MD, Brodie M J, Mattson RH, et al. Topiramate, carbamazepine and valproate monotherapy : double-blind comparison in newly diagnosed epilepsy[J]. Acta Neurol Scand, 2003, 107(3) :165-175.
  • 8Marson AG, AI-Khamsi AM, Alwaidh M, et al. The SANAD study of effectiveness of valpreate, lamotrigine, or topiramate forgeneralized and unclassifiable epilepsy: an unblinded randomized controlled trial[J]. Lancet, 2007, 369(9566) :1016-1026.
  • 9Berg AT, Berkovic SF, Brodie M J, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE commission on classification and terminology, 2005- 2009[J]. Epilepsia, 2010, 51 (4) :676-685.
  • 10Abimbola S, Martiniuk AL, Hackett ML, et al. Early predictors of remission in newly diagnosed epilepsy : a systematie approach to reviewi@ prognostic factor studies[J].Neurol Res, 2014, 36 (1) :1-12.

引证文献3

二级引证文献64

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部